RxDoctor Payments Data

Vinod Chainani, MD

Interventional Cardiology · Miami, FLNPI 1174830178

Payments from drug & device makers

$95,850in general payments, 2019–2025

Across 235 payments — averaging $407.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$43K
  • Novartis$27K
  • Surmodics, Inc.$10K
  • Cook Medical LLC$4K
  • Medtronic$2K
  • Philips North America LLC$1K
  • plus $8K from 33 others

What the payments were for

  • Consulting fees$7,22511%
  • Grants$4,4887%
  • Travel & lodging$2,4734%
  • Food & beverage$12,34918%
  • Education$6581%
  • Other$41,33360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,850 in reported general payments places this provider in the 80th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$305,493
Medicare patients
293
Services billed
926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan70$86,969
EliquisApixaban77$85,420
XareltoRivaroxaban88$72,518
FarxigaDapagliflozin Propanediol40$44,264
BrilintaTicagrelor40$31,165
MounjaroTirzepatide13$14,081
Cilostazol139$2,860
Ranolazine ErRanolazine23$1,985
Atorvastatin Calcium241$1,955
ClopidogrelClopidogrel Bisulfate172$1,622
Doxazosin Mesylate84$1,135
Nifedipine ErNifedipine51$743
Metoprolol Succinate119$712
Bumetanide36$584
Rosuvastatin Calcium51$490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$27,496$86,96970 claims
PfizerEliquis$279$85,42077 claims
AstraZenecaFarxiga, Brilinta$501$75,43080 claims
Johnson & JohnsonXarelto$390$72,51888 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →